Articles By Anuja Singh
How Roche’s $55 Million Bet on Manifold Bio’s AI Brain-Shuttle Platform Unlock the Next…
Key Highlights• Roche deepens its AI-first drug discovery strategy with a foundational partnership targeting blood-brain barrier (BBB) breakthroughs•…
By
Will Lilly’s AI Supercomputer with NVIDIA Become the Breakthrough That Redefines Competitive Timelines in…
• Lilly partners with NVIDIA to build what it calls the most powerful AI supercomputer operated by a…
Could Merck’s USD 349M Collaboration with Variational AI and Its Enki™ Platform Mark a…
Key Highlights A Strategic Alliance Targeting Hard-to-Crack Therapeutic SpaceVariational AI announced a major collaboration with Merck to deploy…
Could Excelsior Sciences’ $95M AI Surge Redefine How Fast Small-Molecule Drugs Reach the Market?
Key Highlights • $95M funding round positions Excelsior to compress multi-month chemistry cycles into weeks, reshaping competitive timelines…
Will Novartis’s $12 Billion Avidity Deal Ignite a New Era of AI-Powered RNA Therapeutics…
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest…
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine Drug Discovery Timelines and Ignite a…
Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions of experiments to…
How Roche’s $55 Million Bet on Manifold Bio’s AI Brain-Shuttle Platform Unlock the Next…
Key Highlights• Roche deepens its AI-first drug discovery strategy with a foundational partnership targeting blood-brain barrier (BBB) breakthroughs•…
Will Lilly’s AI Supercomputer with NVIDIA Become the Breakthrough That Redefines Competitive Timelines in…
• Lilly partners with NVIDIA to build what it calls the most powerful AI supercomputer operated by a…
Could Merck’s USD 349M Collaboration with Variational AI and Its Enki™ Platform Mark a…
Key Highlights A Strategic Alliance Targeting Hard-to-Crack Therapeutic SpaceVariational AI announced a major collaboration with Merck to deploy…
Could Excelsior Sciences’ $95M AI Surge Redefine How Fast Small-Molecule Drugs Reach the Market?
Key Highlights • $95M funding round positions Excelsior to compress multi-month chemistry cycles into weeks, reshaping competitive timelines…
Will Novartis’s $12 Billion Avidity Deal Ignite a New Era of AI-Powered RNA Therapeutics…
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest…
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine Drug Discovery Timelines and Ignite a…
Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions of experiments to…